PUBLISHER: Renub Research | PRODUCT CODE: 1246757
PUBLISHER: Renub Research | PRODUCT CODE: 1246757
Japan's Diabetes Market will reach US $3.39 Billion in 2028, and it will expand at a CAGR of 2.75% from 2023 to 2028, according to Renub Research. Diabetes is a non-communicable disease caused by high blood glucose levels and is currently one of Japan's most important public health problems. Japan has around 11 million people with diabetes, according to IDF 2021. Aging and obesity contribute to the increase in diabetes prevalence. Of this, the rapidly aging population is a significant concern, which makes disease management a challenge. Apart from disease management, the economic impact of diabetes in Japan is substantial.
Japan has the highest proportion of the aging population globally; almost a quarter of the population is 65 plus. The increase in the geriatric population is an enormous burden for the Japanese government because the prevalence of the aging disease is rising rapidly. So the Japanese government has prioritized dealing with an aging population, and it is expected that government will allocate a skyrocketed healthcare budget in 2025 for aging. Therefore rising prevalence and increased public expenditure will boost Japan's diabetes Market. Japan, Diabetes Market was US$ 2.88 Billion in 2022.
Japan has a low incidence of type 1 diabetes because the Japanese are genetically homogeneous. However, Japan has one of the largest elderly populations in the world, which is more susceptible to the onset of type 2 diabetes. In addition, there are many contributing factors to diabetes development in Japanese people, including dietary patterns, physical inactivity, smoking, and many others. Therefore, Japan's diabetes care devices are one of the high-potential markets for development.
Japan's Diabetes industry has been divided into SMBG, CGM, and Insulin Pumps. SMBG holds a substantial revenue share owing to the high diabetes incidence rate. In addition, changing lifestyles, unhealthy dietary habits, physical inactivity, and excessive body weight are prominent factors contributing to the disease burden. Thus, the need to monitor blood glucose level for the optimization of treatment regime among these patients drive the japan market revenue. Moreover, a higher prevalence rate across developed countries with awareness regarding SMBG among the type 2 diabetes population will fuel the market revenue.
Even with such colossal healthcare and drug expenditure on the treatment of diabetes, the number of patients undergoing dialysis due to diabetes continues to increase, and the number of chronic dialysis patients in Japan per capita is by far the largest in an international comparison. To reduce ever-increasing social security expenditure, the Government of Japan is attempting to improve the efficiency of healthcare services. The premise of these efforts is that there exists a high degree of waste in the present system. However, the problem lies in the over-provision of health care and extends to under-provision. In recent years, Japan's disease structure has been changing due to the rapid aging of the population and lifestyle changes.
As a result, there are ever-increasing deaths and disabilities associated with non-communicable diseases (NCDs), such as cancer, cardiovascular diseases, and diabetes. Moreover, these NCDs have accounted for more than 30% of national healthcare expenditures. Therefore, in 2000, the Japanese government launched the National Health Promotion Movement in the 21st Century, known as Health Japan 21.
The major players are: Medtronic, Insulet Corporation, Abbott Laboratories, DarioHealth Crop, Dexcom, Inc, Roche Diagnostic, Tandem Diabetes Care.
In June 2022, Sanofi and Health2Sync announced that they would work together on new features such as connected caps for insulin products that can automatically record delivered doses, rather than requiring them to be logged manually, and titration alerts from the app to indicate when a change in insulin dose may be required.
In March 2022, Quantum Operation Inc., a Tokyo-based healthcare IoT startup, presented the world's first non-invasive glucose monitor capable of continuous measurement. It measures the blood sugar from the wrist without any pricks.
Renub Research report titled "Japan Diabetes Market & Forecast, By Self-Monitoring Blood Glucose (SMBG Market by, Test Strips, Lancet, Meter, Blood Glucose Device Users & Reimbursement) Continuous Glucose Monitoring (CGM Market by Components, Glucose Sensor, Transmitter, CGM User, Reimbursement), Insulin Pump (Users, Market & Differentiation Points of Insulin Pump Products, Training Model for Patients & HCP, Reimbursement Policies) Company (Medtronic, Insulet Corporation, Abbott Laboratories, DarioHealth Crop, Dexcom, Inc, Roche Diagnostic, Tandem Diabetes Care)" provides a complete analysis of Japan Diabetes Market.